Development of a Fully Protective Pandemic Avian Influenza Subunit Vaccine in Insect Pupae
Falcón, Ana (Alternative Gene Expression S.L.)
Martínez-Pulgarín, Susana (Alternative Gene Expression S.L.)
López-Serrano, Sergi (Universitat Autònoma de Barcelona. Unitat Mixta d'Investigació IRTA-UAB en Sanitat Animal)
Reytor, Edel (Alternative Gene Expression S.L.)
Cid, Miguel (Alternative Gene Expression S.L.)
Nuñez, Maria del Carmen (Alternative Gene Expression S.L.)
Córdoba, Lorena (Universitat Autònoma de Barcelona. Unitat Mixta d'Investigació IRTA-UAB en Sanitat Animal)
Darji, Ayub (Universitat Autònoma de Barcelona. Unitat Mixta d'Investigació IRTA-UAB en Sanitat Animal)
Escribano, José M. (Alternative Gene Expression S.L.)

Data:	2024
Resum:	In this study, we pioneered an alternative technology for manufacturing subunit influenza hemagglutinin (HA)-based vaccines. This innovative method involves harnessing the pupae of the Lepidoptera Trichoplusia ni (T. ni) as natural biofactories in combination with baculovirus vectors (using CrisBio ® technology). We engineered recombinant baculoviruses encoding two versions of the HA protein (trimeric or monomeric) derived from a pandemic avian H7N1 virus A strain (A/chicken/Italy/5093/99). These were then used to infect T. ni pupae, resulting in the production of the desired recombinant antigens. The obtained HA proteins were purified using affinity chromatography, consistently yielding approximately 75 mg/L of insect extract. The vaccine antigen effectively immunized poultry, which were subsequently challenged with a virulent H7N1 avian influenza virus. Following infection, all vaccinated animals survived without displaying any clinical symptoms, while none of the mock-vaccinated control animals survived. The CrisBio ® -derived antigens induced high titers of HA-specific antibodies in the vaccinated poultry, demonstrating hemagglutination inhibition activity against avian H7N1 and human H7N9 viruses. These results suggest that the CrisBio ® technology platform has the potential to address major industry challenges associated with producing recombinant influenza subunit vaccines, such as enhancing production yields, scalability, and the speed of development, facilitating the global deployment of highly effective influenza vaccines.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Pandemic influenza ; Baculovirus ; Trichoplusia ni ; Insect pupae ; Subunit vaccine
Publicat a:	Viruses, Vol. 16 (may 2024) , ISSN 1999-4915

DOI: 10.3390/v16060829
PMID: 38932122

14 p, 2.5 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Centre de Recerca en Sanitat Animal (CReSA-IRTA)
Articles > Articles de recerca
Articles > Articles publicats